Skip to main content

Integrated BioPharma, Inc.

corporate_fare Company Profile

Integrated BioPharma, Inc.

INBP·OTC·Life Sciences·CIK 0001016504

Integrated BioPharma, Inc. is primarily engaged in the business of manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. The company's customers are located primarily in the United States and Luxembourg. Integrated BioPharma, Inc. was originally incorporated on August 31, 1995, as Chem International, Inc., changed its name to Integrated Health Technologies, Inc. on December 5, 2000, and then to Integrated BioPharma, Inc. on January 29, 2003. The company continues to operate as Chem International, Inc. with certain customers and vendors. The company's business segments include: (a) Contract Manufacturing, operated by Manhattan Drug Company, Inc. (MDC), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. (b) Other Business Lines, which encompasses the operations of MDC Warehousing and Distribution, Inc., a provider of warehousing and fulfillment services; Chem International, Inc. (Chem), a distributor of certain raw materials for DSM Nutritional Products LLC and the company's holding entity; and all other inactive subsidiaries. In the fiscal years ended June 30, 2026, and 2025, approximately 90% and 84%, respectively, of the company's consolidated net sales were concentrated among two customers: Life Extension Quality Supplements and Vitamins, Inc. (Life Extension) and Herbalife Nutrition LTD (Herbalife). Both customers are part of the Contract Manufacturing Segment. Life Extension and Herbalife represented approximately 68% and 25%, respectively, of the Contract Manufacturing Segment's net sales in the fiscal year ended June 30, 2026, and approximately 62% and 26%, respectively, in the fiscal year ended June 30, 2025.

Integrated BioPharma, Inc. (OTC:INBP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 9 items for INBP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 7/10. Across its 9 most recent items scored 7 or higher, the top rating is 9/10, with 5 rated 8 or above. Recent SEC coverage for INBP spans 10-Q, DEF 14A, 10-K, 8-K.

Recent high-impact activity:

  • Integrated BioPharma Q1 Swings to $691K Net Loss as Sales Fall 21.9%
  • Proxy Asks Shareholders to Approve 7.5M-Share Equity Plan at Nov 30 Meeting
  • Integrated BioPharma FY2026: Sales Drop 19%, Gross Margin Collapses to 1.8%, Loan Covenant Breached
  • Secures Extension of $4M Credit Line, Adds New $250k Equipment Facility
  • INTEGRATED BIOPHARMA Reports Significant Quarterly and Nine-Month Losses Amidst Steep Revenue Decline

Financial Snapshot

Fiscal year ended June 30, 2026
Revenue
$43.87M
Net Income
-$2.84M
Diluted EPS
-$0.09
Op. Cash Flow
$1.24M
Free Cash Flow
$895K
Gross Profit
$800K
Operating Income
-$2.71M
Cash & Equivalents
$4.47M
Debt / Equity
0.00×
Net Margin
-6.5%
Shares Outstanding
31.06M sh
Source: 10-K · filed 2026-09-25 · accession 0001437749-26-031241

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 509 shares in INBP as of the October 30, 2026 settlement, unchanged from the prior period — about 1.0 days to cover at its recent average daily volume. On November 19, 2026, 99.5% of INBP volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)509 shares as of October 30, 2026
Change vs prior period 0.0%
Days to cover1.00 at avg daily volume of 6,157
Daily short volume (FINRA facilities)99.5% of 28,213 shares on November 19, 2026

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with I →
$0.16
52-week range · as of 2026-11-13 $0.1375 – $0.4199
Market cap
$4.97M
Volume
28.2K (1.8× avg)
3-mo avg 15.9K
Live data · 2026-11-22 04:08 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed INBP - Latest Insights

INBP
Nov 13, 2026, 11:52 AM EST
Filing Type: 10-Q
Importance Score:
7
Updated Nov 13, 12:12 PM ET — Integrated BioPharma's quarterly revenue fell 22% to $9.9M from $12.7M a year earlier, with top two customers at 88% of revenue versus 87%.
Price at Filing: $0.16514
Real-time Price: $0.160 info
Change: -$0.00514 (-3%) info
Market Cap: $4.97M info
INBP
Oct 28, 2026, 3:07 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $0.165
Real-time Price: $0.160 info
Change: -$0.0050 (-3%) info
Market Cap: $4.97M info
INBP
Sep 25, 2026, 4:36 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $0.1837
Real-time Price: $0.160 info
Change: -$0.0237 (-13%) info
Market Cap: $4.97M info
INBP
Jul 02, 2026, 10:37 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.1797
Real-time Price: $0.160 info
Change: -$0.0197 (-11%) info
Market Cap: $4.97M info
INBP
May 08, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.250
Real-time Price: $0.160 info
Change: -$0.090 (-36%) info
Market Cap: $4.97M info
INBP
Apr 17, 2026, 4:17 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $0.280622
Real-time Price: $0.160 info
Change: -$0.120622 (-43%) info
Market Cap: $4.97M info
INBP
Apr 17, 2026, 3:48 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
9
Price at Filing: $0.280622
Real-time Price: $0.160 info
Change: -$0.120622 (-43%) info
Market Cap: $4.97M info
INBP
Feb 18, 2026, 4:23 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.2987
Real-time Price: $0.160 info
Change: -$0.1387 (-46%) info
Market Cap: $4.97M info
INBP
Feb 11, 2026, 4:24 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.300
Real-time Price: $0.160 info
Change: -$0.140 (-47%) info
Market Cap: $4.97M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets